ValuEngine Upgrades Pro-Dex (PDEX) to Buy
ValuEngine upgraded shares of Pro-Dex (NASDAQ:PDEX) from a hold rating to a buy rating in a research report report published on Thursday.
Shares of NASDAQ:PDEX opened at $10.30 on Thursday. The company has a market capitalization of $43.10 million, a P/E ratio of 19.04 and a beta of -0.20. Pro-Dex has a fifty-two week low of $6.05 and a fifty-two week high of $11.00.
Pro-Dex (NASDAQ:PDEX) last issued its earnings results on Thursday, August 30th. The medical instruments supplier reported $0.22 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.16. Pro-Dex had a net margin of 9.94% and a return on equity of 13.54%.
Pro-Dex, Inc, together with its subsidiaries, designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and machined parts.
Recommended Story: Discover Your Risk Tolerance
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.